CIBC Bancorp USA
IMRX icon

CIBC Bancorp USA’s Immuneering IMRX Stock Holding History

CIBC Bancorp USA’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$96.6K Sell
23,586
-874
-4% -$4.13K ﹤0.01% 2104
2026
Q2 		$122K Buy
24,460
+960
+4% +$4.86K ﹤0.01% 1838
2026
Q1 		$124K Buy
+23,500
New +$120K ﹤0.01% 1668

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

CIBC Bancorp USA's IMRX Position: Q3 2026 in Review

CIBC Bancorp USA reduced its Immuneering (IMRX) stake by 3.6% in Q3 2026, selling an estimated $4.13K and leaving 23,586 shares worth $96.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

CIBC Bancorp USA first reported a position in IMRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $124K in Q1 2026. 96 funds tracked by Wall St. Rank hold IMRX as of Q3 2026.

  • CIBC Bancorp USA held 23,586 shares of Immuneering worth $96.6K as of Q3 2026.
  • CIBC Bancorp USA sold 874 Immuneering shares in Q3 2026, an estimated $4.13K.
  • Immuneering made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2104 holding.
  • CIBC Bancorp USA first reported a position in Immuneering in Q1 2026 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Immuneering position peaked at $124K in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Immuneering as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.